North America Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market Report and Forecast 2024-2032

North America Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market Analysis

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a treatable autoimmune disorder, with around 80% of people responding to one or more of the available treatments. Intravenous and subcutaneous immunoglobulins, corticosteroids, and plasma exchanges are the first-line evidence-based therapies for the autoimmune disorder. In cases of refractoriness or perceived overdependence on first-line therapies, cyclophosphamide, rituximab, and mycophenolate mofetil are commonly used. Pharmaceutical companies in North America are actively investing in the research and development of new treatments for CIDP, which is driving innovation in the global chronic inflammatory demyelinating polyneuropathy therapeutics market. Further, the rising advancements in personalized medicine and the growing demand for targeted therapies are expected to propel the North America chronic inflammatory demyelinating polyneuropathy therapeutics market growth.

Chronic inflammatory demyelinating polyneuropathy can lead to symptoms such as symmetric weakness or loss of feeling in the arms and legs. One-third of patients with CIDP will need a wheelchair if proper treatment is not given which indicates the need for potent treatments. In April 2024, a global immunology company argenx SE announced a potential US Food and Drug Administration (FDA) approval and launch plans for a subcutaneous version of its leading asset, Vyvgart Hytrulo, to treat chronic inflammatory demyelinating polyneuropathy. The company revealed positive data from its late stage ADHERE trial that showed rapid clinical improvement and reduced risk of relapse of CIDP patients who took Vyvgart. Around 67% of participants responded to the drug and 81% experienced at least one point of improvement over baseline on their Treatment disability scores and Inflammatory Neuropathy Cause. The increased development of such safe and effective medications is poised to boost the North America chronic inflammatory demyelinating polyneuropathy therapeutics market demand in the forecast period.

The rise in approvals of novel therapeutics by health regulatory authorities is one of the major market trends. In January 2024, global biopharmaceutical company Takeda Pharmaceuticals received FDA approval for its subcutaneous immunoglobin (SCIG) infusion HYQVIA (Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase) as maintenance therapy for adult chronic inflammatory demyelinating polyneuropathy patients. The approval is based on the Phase 3 ADVANCE-CIDP 1 study that demonstrated HYQVIA superiority over placebo in preventing CIDP relapse. Thus, the presence of a supportive regulatory system is anticipated to expedite the market entry of new and advanced therapeutics, which will ultimately bolster the market growth.

North America Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market Report Snapshots

North America Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market Size

North America Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market Analysis

North America Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Companies